Recent Updates
Recently added Catalysts
AVR Positive Sentiment

Anteris Announces Late-Breaking PCR London Valves Data Release: One-Year DurAVR THV Outcomes in 100 Patients

Key Takeaway: Anteris Technologies announced that Dr. Rishi Puri will present one-year outcomes for the DurAVR Transcatheter Heart Valve at PCR London Valves. The study includes data from 100 patients with severe aortic stenosis. The DurAVR THV is designed to replicate normal aortic blood flow using advanced biomimetic technology.

Market Sentiment Analysis

POSITIVE FACTORS

  • Presentation of one-year outcomes for DurAVR THV.
  • DurAVR THV designed to mimic healthy aortic valve function.
  • ADAPT tissue technology has been clinically used for over 10 years.
  • Pooled data from 100 patients with severe aortic stenosis.

Full Press Release Details

MINNEAPOLIS and BRISBANE, Australia, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (Nasdaq: AVR; ASX: AVR) today announced that Rishi Puri, MD, PhD, Cleveland Clinic, will present one-year clinical and hemodynamic outcomes for the DurAVR® Transcatheter Heart Valve (THV) in a late-breaking session at PCR London Valves, held November 22–24, 2026, in London, United Kingdom.
The presentation will report one-year clinical and hemodynamic outcomes from a pooled cohort of 100 patients with severe aortic stenosis who received the DurAVR THV. The DurAVR THV is a biomimetic, balloon-expandable valve and a new class of transcatheter aortic valve replacement (TAVR).
Session details are as follows: Session: TAVI Hotline – Part 1 Track: Hotline / Late-Breaking Trials Date and time: Sunday, November 22, 2026, 9:30 AM – 10:30 AM GMT/UTC+0 Location: Dubai Room Title: One-Year Clinical and Hemodynamic Outcomes of a Novel Biomimetic Balloon-Expandable THV in Small Aortic Annuli Presenter: Rishi Puri, MD, PhD, Cleveland Clinic

About Anteris

Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global healthcare company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients.
Anteris’ lead product, the DurAVR THV, was designed in collaboration with the world’s leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. DurAVR THV is made using a single piece of molded ADAPT® tissue, Anteris’ patented anti-calcification tissue technology. ADAPT tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide. The DurAVR THV System is comprised of the DurAVR valve, the ADAPT tissue, and the balloon-expandable ComASUR® Delivery System.

Forward-Looking Statements

This announcement contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. Forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “budget,” “target,” “aim,” “strategy,” “plan,” “guidance,” “outlook,” “may,” “should,” “could,” “will,” “would,” “will be,” “will continue,” “will likely result” and similar expressions, although not all forward-looking statements contain these identifying words. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including those described under “Risk Factors” in Anteris’ Annual Report on Form 10-K for the fiscal period ended December 31, 2025 that was filed with the Securities and Exchange Commission and ASX. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, Anteris does not assume any obligation to update any of these forward-looking statements to conform these statements to actual results or revised expectations.
For more information:
Global Investor Relations Investor Relations (US)
investors@anteristech.com mchatterjee@bplifescience.com
Debbie Ormsby Malini Chatterjee, Ph.D.
Anteris Technologies Global Corp. Blueprint Life Science Group
+61 1300 550 310 | +61 7 3152 3200 +1 917 330 4269
Website www.anteristech.com
X @AnterisTech
LinkedIn https://www.linkedin.com/company/anteristech

Frequently Asked Questions

What is the DurAVR THV?

The DurAVR THV is a biomimetic, balloon-expandable valve for aortic stenosis.

When will the outcomes be presented?

The outcomes will be presented on November 22, 2026.

How many patients were involved in the study?

The study involved a pooled cohort of 100 patients.

What technology is used in the DurAVR THV?

It uses ADAPT tissue technology, which is FDA-cleared.

Last updated: Nov 16, 2026